Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma
Authors:
- Sigbjørn SmelandSSSigbjørn Smeland
- Øyvind S BrulandØBØyvind S Bruland
- Lars HjorthLHLars Hjorth
- Otte BrosjöOBOtte Brosjö
- Bodil BjerkehagenBBBodil Bjerkehagen
- Gustaf ÖsterlundhGÖGustaf Österlundh
- Åke JakobsonÅJÅke Jakobson
- Kirsten Sundby HallKHKirsten Sundby Hall
- Odd R MongeOMOdd R Monge
- Olle BjörkOBOlle Björk
- Thor A AlvegaardTAThor A Alvegaard
Open Access
- 24 March 2011
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 82 (2) , 211-216
Abstract
The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m²), cisplatin (90 mg/m²), and doxorubicin (75 mg/m²). 3 cycles were administered postoperatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m²) as a salvage strategy. With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders. Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences.Keywords
This publication has 24 references indexed in Scilit:
- International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience2009
- Local recurrence and local control of non‐metastatic osteosarcoma of the extremities: A 27‐year experience in a single institutionJournal of Surgical Oncology, 2007
- Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma IntergroupJNCI: Journal of the National Cancer Institute, 2007
- Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma GroupsJournal of Clinical Oncology, 2005
- Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)Journal of Clinical Oncology, 2005
- Scandinavian Sarcoma Group Osteosarcoma Study SSG VIIIEuropean Journal of Cancer, 2003
- Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term SurvivalJournal of Clinical Oncology, 2003
- Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2002
- Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?European Journal of Cancer, 1996
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986